diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-6023diaendo-6023Research ArticleСтатьиArticlesТерапия двухфазным инсулином аспарт 30/70 (НовоМикс? 30) улучшает гликемический контроль у пациентов с сахарным диабетом 2 типа: данные российской когорты пациентов наблюдательной программы IMPROVE? - программы по изучению безопасности и эффективности двухфазного инсулина аспарт 30 в рутинной клинической практикеTherapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practiceШестаковаМарина ВладимировнаShestakovaMarina Vladimirovnanephro@endocrincentr.ruБалланАкилBallanAkilpost@endocrincentr.ruФГУ Эндокринологический научный центр, МоскваEndocrinological Research Centre, MoscowКомпания «Ново Нордиск», МоскваNovo Nordisk, Moscow201015032010131№1 (2010)92100Copyright © Шестакова М.В., Баллан А., 20102010Шестакова М.В., Баллан А.Shestakova M.V., Ballan A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6023сахарный диабет 2 типаинсулинотерапияаспарт 30 (НовоМикс 30)type 2 diabetes mellitusinsulin therapyaspart 30 (NovoMix 30)ReferencesUK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 52(9131). - Р. 837-853.UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 52(9131). - Р. 837-853.Rodbard H.W., Davidson J.A. Glycemic Control Algorithm, Statement by an American Association of Clinical Endocrinologists /American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: Аn Algorithm for Glycemic Control // Endocr. Pract. - 2009. - 15(№6). - Р. 541.Rodbard H.W., Davidson J.A. Glycemic Control Algorithm, Statement by an American Association of Clinical Endocrinologists /American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: Аn Algorithm for Glycemic Control // Endocr. Pract. - 2009. - 15(№6). - Р. 541.Алгоритмы специализированной медицинской помощи больным са- харным диабетом / Под ред. акад. Дедова И.И. и проф. Шестаковой М.В.- М., 2009. - 104 с.Алгоритмы специализированной медицинской помощи больным са- харным диабетом / Под ред. акад. Дедова И.И. и проф. Шестаковой М.В.- М., 2009. - 104 с.Standards of Medical Care in Diabetes-2009. // Diabetes Care. - 2009. - 32 (spl. 1). - S13-S61.Standards of Medical Care in Diabetes-2009. // Diabetes Care. - 2009. - 32 (spl. 1). - S13-S61.Mazze et al. Staged Diabetes Management: a systematic approach, Second Edition (Revised). // International Diabetes Center. - 2007. - P. 55.Mazze et al. Staged Diabetes Management: a systematic approach, Second Edition (Revised). // International Diabetes Center. - 2007. - P. 55.Nathan D.M. Finding new treatments for diabetes - how many, how fast… how good? // N. Engl. J. Med. - 2007. - 356. - Р. 437-440.Nathan D.M. Finding new treatments for diabetes - how many, how fast… how good? // N. Engl. J. Med. - 2007. - 356. - Р. 437-440.Wright A., Burden A.C. et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) // Diabetes Care. - 2002. - 25. - Р. 330-336.Wright A., Burden A.C. et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) // Diabetes Care. - 2002. - 25. - Р. 330-336.Hermansen K., Davies M. et al. A 26-week, randomized, parallel, treatto-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetes Care. - 2006. - 29(6). - Р. 1269-1274.Hermansen K., Davies M. et al. A 26-week, randomized, parallel, treatto-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetes Care. - 2006. - 29(6). - Р. 1269-1274.Holman R.R., Thorne K.I. et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes // N. Engl. J. Med. - 2007. - 357(17). - Р. 1716-1730.Holman R.R., Thorne K.I. et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes // N. Engl. J. Med. - 2007. - 357(17). - Р. 1716-1730.Philis-Tsimikas A., Charpentier G. et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes // Clin. Ther. - 2006. - 28(10). - Р. 1569-1581.Philis-Tsimikas A., Charpentier G. et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes // Clin. Ther. - 2006. - 28(10). - Р. 1569-1581.Rosenstock J., Davies M., Home P.D. et al. A randomised, 52-week, treatto- target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetologia. - 2008. - 51(3). - Р. 408-416.Rosenstock J., Davies M., Home P.D. et al. A randomised, 52-week, treatto- target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetologia. - 2008. - 51(3). - Р. 408-416.Strojek K., Bebakar W.M.W. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT // Cur. Med. Research & Opinion. - 2009. - 25 (12). - P. 2887- 2894.Strojek K., Bebakar W.M.W. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT // Cur. Med. Research & Opinion. - 2009. - 25 (12). - P. 2887- 2894.Raskin P., Allen E., Hollander P. et all. INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs // Diabetes Care. - 2005. - 28(2). - P. 260-265.Raskin P., Allen E., Hollander P. et all. INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs // Diabetes Care. - 2005. - 28(2). - P. 260-265.Kann P.H., Wascher T. et all. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride // Exp. Clin. Endocrinol. Diabetes. - 2006. - 114(9). - P. 527-532.Kann P.H., Wascher T. et all. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride // Exp. Clin. Endocrinol. Diabetes. - 2006. - 114(9). - P. 527-532.Ligthelm R.J., Borzi V. et al. Importance of observational studies in clinical practice // Clin. Ther. - 2007. - 29. - P. 1284-1292.Ligthelm R.J., Borzi V. et al. Importance of observational studies in clinical practice // Clin. Ther. - 2007. - 29. - P. 1284-1292.Khutsoane D., Sharma S.K., Almustafa M. et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. - 2008. - 10. - P. 212-222.Khutsoane D., Sharma S.K., Almustafa M. et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. - 2008. - 10. - P. 212-222.Shaban J., Hansen J.B., Wenying Y. NovoMix 30 (BIAsp 30) Improves Glycemic Control in Type 2 Diabetes: Results from the IMPROVE Study // Diabetes Care. - 2008. - 31(suppl. 1). - P. S12-S54.Shaban J., Hansen J.B., Wenying Y. NovoMix 30 (BIAsp 30) Improves Glycemic Control in Type 2 Diabetes: Results from the IMPROVE Study // Diabetes Care. - 2008. - 31(suppl. 1). - P. S12-S54.Valensi P., Benroubbi M., Borzi V., et al. The IMPROVE™ Study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts // Int. J. Clin. Pract. - 2008. - 62. - Р. 1809-1819.Valensi P., Benroubbi M., Borzi V., et al. The IMPROVE™ Study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts // Int. J. Clin. Pract. - 2008. - 62. - Р. 1809-1819.Шестакова М.В., Баллан А. Наблюдательная программа IMPROVE ™ - безопасность и эффективность двухфазного инсулина ас- парт 30 в рутинной клинической практике: Обзор исходных характеристик российской когорты пациентов // Сахарный диабет. - 2009. - 4. - C. 93-98.Шестакова М.В., Баллан А. Наблюдательная программа IMPROVE ™ - безопасность и эффективность двухфазного инсулина ас- парт 30 в рутинной клинической практике: Обзор исходных характеристик российской когорты пациентов // Сахарный диабет. - 2009. - 4. - C. 93-98.Ligthelm R.J., Borzi V. et al. Importance of observational studies in clinical practice // Clin. Ther. 2007; 29. - P. 1284-1292.Ligthelm R.J., Borzi V. et al. Importance of observational studies in clinical practice // Clin. Ther. 2007; 29. - P. 1284-1292.Jang H.C., Guler S., Shestakova V. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Result from a subanalysis of the PRESENT study // Int. J. Clini. Pract. - 2008. - 62. - P. 1013-1018.Jang H.C., Guler S., Shestakova V. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Result from a subanalysis of the PRESENT study // Int. J. Clini. Pract. - 2008. - 62. - P. 1013-1018.Cryer P.E., Davis S.N., Shamoon H. Hypoglycemia in diabetes // Diabetes Care. - 2003. - 26(6). - P. 1902-1912.Cryer P.E., Davis S.N., Shamoon H. Hypoglycemia in diabetes // Diabetes Care. - 2003. - 26(6). - P. 1902-1912.Bartley P.C., Bogoev M. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial // Diabetic Medicine. - 2008. - 25. - P. 442- 449.Bartley P.C., Bogoev M. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial // Diabetic Medicine. - 2008. - 25. - P. 442- 449.Wright A., Burden A.C., Paisey R.B. et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) // Diabetes Care 2002; 25. - P. 330-336.Wright A., Burden A.C., Paisey R.B. et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) // Diabetes Care 2002; 25. - P. 330-336.DCCT Research Group // New. Eng. J. Med. - 1993. - 329. - P. 977- 986.DCCT Research Group // New. Eng. J. Med. - 1993. - 329. - P. 977- 986.Beaser R.S., Wolpert H., Ghiloni S. Technologies That Optimize Glucose Control: Monitoring and Insulin Delivery. The Joslin Diabetes Center, Boston. MedScape CME 2009, CME/CE Released: 07/29/2009.Beaser R.S., Wolpert H., Ghiloni S. Technologies That Optimize Glucose Control: Monitoring and Insulin Delivery. The Joslin Diabetes Center, Boston. MedScape CME 2009, CME/CE Released: 07/29/2009.Cobden D., Lee W.C., Balu S., Joshi A.V., Pashos C.L. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus // Pharmacotherapy. - 2007. - 27. - P. 948-962.Cobden D., Lee W.C., Balu S., Joshi A.V., Pashos C.L. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus // Pharmacotherapy. - 2007. - 27. - P. 948-962.Lee W.C., Balu S., Cobden D. et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data // Clin. Ther. - 2006. - 28. - P. 1712-1725.Lee W.C., Balu S., Cobden D. et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data // Clin. Ther. - 2006. - 28. - P. 1712-1725.Garber et al. Attainment of glycaemic goals in type 2 diabetes with once, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1- 2-3 study) // Diabetes Obes. Metab. - 2006. - 8. - P. 58-66.Garber et al. Attainment of glycaemic goals in type 2 diabetes with once, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1- 2-3 study) // Diabetes Obes. Metab. - 2006. - 8. - P. 58-66.Liebl A., Prager R., Kaiser M. et al. The PREFER study: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target <7,0% EASD 2006, Poster 998.Liebl A., Prager R., Kaiser M. et al. The PREFER study: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target <7,0% EASD 2006, Poster 998.
The authors declare that there are no conflicts of interest present.